MA51155A - Compositions comprenant des polyribonucléotides circulaires et leurs utilisations - Google Patents
Compositions comprenant des polyribonucléotides circulaires et leurs utilisationsInfo
- Publication number
- MA51155A MA51155A MA051155A MA51155A MA51155A MA 51155 A MA51155 A MA 51155A MA 051155 A MA051155 A MA 051155A MA 51155 A MA51155 A MA 51155A MA 51155 A MA51155 A MA 51155A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions consisting
- circular polyribonucleotides
- polyribonucleotides
- circular
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599547P | 2017-12-15 | 2017-12-15 | |
| US201862676688P | 2018-05-25 | 2018-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51155A true MA51155A (fr) | 2020-10-21 |
Family
ID=66820668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051155A MA51155A (fr) | 2017-12-15 | 2018-12-14 | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
Country Status (13)
| Country | Link |
|---|---|
| US (9) | US12357653B2 (fr) |
| EP (1) | EP3724208A4 (fr) |
| JP (2) | JP2021508490A (fr) |
| KR (1) | KR20200127152A (fr) |
| CN (3) | CN120774994A (fr) |
| AU (2) | AU2018385757B2 (fr) |
| BR (1) | BR112020011670A2 (fr) |
| CA (1) | CA3084824A1 (fr) |
| IL (2) | IL316195A (fr) |
| MA (1) | MA51155A (fr) |
| MX (1) | MX2020006150A (fr) |
| SG (1) | SG11202005060YA (fr) |
| WO (1) | WO2019118919A1 (fr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006150A (es) | 2017-12-15 | 2020-11-11 | Flagship Pioneering Innovations Vi Llc | Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. |
| KR20210018323A (ko) | 2018-06-06 | 2021-02-17 | 매사추세츠 인스티튜트 오브 테크놀로지 | 진핵 세포에서의 번역을 위한 원형 rna |
| KR20210135265A (ko) * | 2019-03-04 | 2021-11-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드 및 그의 약제학적 조성물 |
| CN115806976A (zh) * | 2019-03-20 | 2023-03-17 | 中国科学院上海营养与健康研究所 | 利用环形rna进行蛋白翻译及其应用 |
| EP3946466A2 (fr) | 2019-03-25 | 2022-02-09 | Flagship Pioneering Innovations VI, LLC | Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées |
| WO2020198337A1 (fr) * | 2019-03-25 | 2020-10-01 | Ohio State Innovation Foundation | Séquences d'arnm modifiées et leurs utilisations |
| WO2020237227A1 (fr) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Compositions et procédés d'arn circulaire |
| US20220257794A1 (en) * | 2019-06-14 | 2022-08-18 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
| US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| US20220296729A1 (en) | 2019-06-19 | 2022-09-22 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
| CN112662659B (zh) * | 2019-10-15 | 2022-08-19 | 武汉核圣生物技术有限公司 | 一种普适性的mRNA体外环化方法 |
| EP4048789A4 (fr) * | 2019-10-22 | 2022-12-14 | The Regents of The University of California | Modulation de la traduction des récepteurs des cellules immunitaires modifiées à l'aide d'éléments de séquence non codants |
| AU2020395111A1 (en) * | 2019-12-02 | 2022-06-02 | The Regents Of The University Of California | Engineering circular guide RNAs |
| WO2021113777A2 (fr) | 2019-12-04 | 2021-06-10 | Orna Therapeutics, Inc. | Méthodes et compositions d'arn circulaire |
| TW202142239A (zh) * | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 包含環狀多核糖核苷酸之組合物之遞送 |
| EP4096682A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions de translation et procédés d'utilisation associés |
| JP2023518295A (ja) * | 2020-03-20 | 2023-04-28 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| US20240042015A1 (en) * | 2020-05-19 | 2024-02-08 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| CA3179444A1 (fr) * | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Compositions immunogenes et leurs utilisations |
| EP4153152A1 (fr) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production d'anticorps polyclonaux humains |
| AU2021275223A1 (en) * | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| CN111733243A (zh) * | 2020-06-29 | 2020-10-02 | 中山大学孙逸仙纪念医院 | 一种提高CircRNA检测准确率的方法 |
| CN116194581A (zh) * | 2020-07-01 | 2023-05-30 | 艾勒维生技公司 | 使用环状rna进行细胞重编程的组合物和方法 |
| KR20230066000A (ko) | 2020-08-12 | 2023-05-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼 |
| AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| IL303892A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Innovations V Inc | In vitro assembly of RNA-encapsulating enalavirus capsids |
| CN112562788B (zh) * | 2020-12-28 | 2022-06-28 | 上海交通大学 | 一种环状rna-rna结合蛋白关系预测模型构建方法 |
| KR102442946B1 (ko) | 2021-03-10 | 2022-09-15 | 알지노믹스 주식회사 | 자가 환형화 rna 구조체 |
| AR125217A1 (es) | 2021-03-26 | 2023-06-28 | Flagship Pioneering Innovations Vii Llc | Producción de polirribonucleótidos circulares en un sistema procariota |
| EP4314289A1 (fr) | 2021-03-26 | 2024-02-07 | Flagship Pioneering Innovations VII, LLC | Production de polyribonucléotides circulaires dans un système procaryote |
| TW202300650A (zh) | 2021-03-26 | 2023-01-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 真核系統中環狀多核糖核苷酸的產生 |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| JP2024523054A (ja) | 2021-05-18 | 2024-06-26 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 環状ポリリボヌクレオチドを濃縮する方法 |
| JP2024521304A (ja) | 2021-05-18 | 2024-05-31 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 環状ポリリボヌクレオチドを濃縮する方法 |
| WO2023288288A1 (fr) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Constructions d'arn synthétiques persistants dotées d'un mécanisme de mise en marche/arrêt pour l'expression régulée et procédés d'utilisation |
| US20230044997A1 (en) | 2021-07-15 | 2023-02-09 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment |
| CN117916371A (zh) | 2021-07-27 | 2024-04-19 | 旗舰创业创新第六有限责任公司 | 用于加工的装置、系统和方法 |
| JP2024534697A (ja) | 2021-09-14 | 2024-09-20 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 非環状脂質及びその使用方法 |
| WO2023044333A1 (fr) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Lipides cycliques et leurs procédés d'utilisation |
| EP4464783A3 (fr) | 2021-09-17 | 2025-01-22 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production de polyribonucléotides circulaires |
| TW202322826A (zh) | 2021-10-18 | 2023-06-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物及方法 |
| EP4422698A1 (fr) * | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| EP4429682A2 (fr) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Bactéries immunostimulatrices pour convertir des macrophages en un phénotype pouvant être traité, et diagnostic compagnon pour identifier des sujets pour un traitement |
| IL312799A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions of varicella-zoster virus and uses thereof |
| IL313004A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus immunogen compositions and their uses |
| EP4436598A2 (fr) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes et leurs utilisations |
| KR102488280B1 (ko) * | 2021-11-25 | 2023-01-16 | 주식회사 뉴클릭스바이오 | 신규한 부목 dna 및 이의 용도 |
| EP4448758A1 (fr) | 2021-12-17 | 2024-10-23 | Flagship Pioneering Innovations VI, LLC | Procédés d'enrichissement en arn circulaire dans des conditions de dénaturation |
| CA3241061A1 (fr) | 2021-12-22 | 2023-06-29 | Alexandra Sophie DE BOER | Compositions et procedes de purification de polyribonucleotides |
| CA3243054A1 (fr) | 2021-12-23 | 2025-04-08 | Renagade Therapeutics Management Inc. | Lipides contraints et procedes d'utilisation associes |
| MX2024007870A (es) | 2021-12-23 | 2024-08-15 | Flagship Pioneering Innovations Vi Llc | Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos. |
| WO2023143541A1 (fr) * | 2022-01-28 | 2023-08-03 | Beijing Changping Laboratory | Vaccins à arn circulaire et leurs procédés d'utilisation |
| CA3255619A1 (fr) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Lipides cycliques et nanoparticules lipidiques (npl) pour l'apport d'acides nucléiques ou de peptides destinés à être utilisés dans la vaccination contre des agents infectieux |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| AU2023320333A1 (en) | 2022-08-01 | 2025-01-16 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| CN120187855A (zh) | 2022-09-06 | 2025-06-20 | 尔知渃米斯股份有限公司 | 自环化rna构建体 |
| EP4585690A1 (fr) | 2022-09-06 | 2025-07-16 | Rznomics Inc. | Structure d'arn à auto-circularisation |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| EP4612296A1 (fr) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de purification de polyribonucléotides |
| TW202430636A (zh) * | 2022-11-08 | 2024-08-01 | 財團法人國家衛生研究院 | 環狀ｒｎａ及其製備方法和應用 |
| AR131008A1 (es) | 2022-11-08 | 2025-02-05 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| KR102584714B1 (ko) | 2022-12-28 | 2023-10-10 | 라이보텍(주) | 덤벨 구조를 이용한 원형 rna 제조 방법 |
| WO2024151685A1 (fr) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation des plaies |
| WO2024151687A1 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Commutateurs génétiques et leur utilisation dans le traitement du cancer |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| EP4648794A2 (fr) | 2023-01-09 | 2025-11-19 | Flagship Pioneering Innovations VII, LLC | Vaccins et procédés associés |
| KR102581491B1 (ko) * | 2023-01-20 | 2023-09-25 | 한국과학기술원 | mRNA의 세포내 안정성과 생합성을 향상시키는 래리엇 캡 구조의 RNA, 및 이의 용도 |
| AU2024212425A1 (en) | 2023-01-27 | 2025-08-07 | Sail Biomedicines, Inc. | A modified lipid composition and uses thereof |
| CN120813699A (zh) * | 2023-01-27 | 2025-10-17 | 卫理公会医院 | 制备和分离环状rna的方法和环状rna组合物 |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024192422A1 (fr) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions immunogènes et leurs utilisations |
| AU2024234874A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| AU2024235803A1 (en) | 2023-03-15 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| WO2024220625A1 (fr) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Administration de polynucléotides à partir de nanoparticules lipidiques comprenant de l'arn et des lipides ionisables |
| WO2024220712A2 (fr) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Compositions vaccinales |
| WO2024220752A2 (fr) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Compositions thérapeutiques à arn |
| WO2024248422A1 (fr) * | 2023-05-26 | 2024-12-05 | 삼성바이오로직스 주식회사 | Nouvelle construction d'acide nucléique contenant une queue poly(a) présentant une structure secondaire ou tertiaire et son utilisation |
| WO2025006684A1 (fr) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Polyribonucléotides circulaires codant pour des polypeptides antifusogènes |
| WO2025042786A1 (fr) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
| WO2025049959A2 (fr) | 2023-09-01 | 2025-03-06 | Renagade Therapeutics Management Inc. | Systèmes et compositions d'édition génique, et méthodes de traitement du syndrome vexas |
| WO2025081042A1 (fr) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Système d'édition de précision basé sur un modèle de nickase-rétron et méthodes d'utilisation |
| WO2025106915A1 (fr) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Polyribonucléotides circulaires codant le peptide 1 de type glucagon (glp-1) et leurs utilisations |
| WO2025106930A1 (fr) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Polyribonucléotides circulaires codant le peptide 2 de type glucagon (glp-2) et leurs utilisations |
| WO2025128871A2 (fr) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition de gènes et en tant que vaccins et agents thérapeutiques |
| WO2025147583A1 (fr) | 2024-01-05 | 2025-07-10 | Sail Biomedicines, Inc. | Ligands pd-1 modifiés |
| WO2025155753A2 (fr) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Système, guides et procédés d'édition de gènes améliorés |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025174765A1 (fr) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et comme vaccins et agents thérapeutiques |
| CN120505342A (zh) * | 2024-02-18 | 2025-08-19 | 中山大学孙逸仙纪念医院 | 一种环状多倍串联rna正义链 |
| WO2025179198A1 (fr) | 2024-02-23 | 2025-08-28 | Sail Biomedicines, Inc. | Polyribonucléotides circulaires et arn linéaires non modifiés à immunogénicité réduite |
| CN118374525B (zh) * | 2024-04-22 | 2025-02-25 | 广州派真生物技术有限公司 | 一种环状rna转录载体及其制备方法和应用 |
| US20250353881A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245111A1 (fr) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Protéines de ciblage d'immunorécepteurs et procédés associés |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1992001813A1 (fr) | 1990-07-25 | 1992-02-06 | Syngene, Inc. | Extension circulaire pour generer plusieurs copies complementaires d'un acide nucleique |
| US5426180A (en) | 1991-03-27 | 1995-06-20 | Research Corporation Technologies, Inc. | Methods of making single-stranded circular oligonucleotides |
| US5877160A (en) | 1991-05-31 | 1999-03-02 | Genta Incorporated | Compositions and methods of treatment of androgen-associated baldness using antisense oligomers |
| US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| EP0773227A1 (fr) | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Collections d'oligomères diverses, utiles pour préparer des médicaments, réactifs diagnostiques pesticides et herbicides |
| CA2127461A1 (fr) | 1992-01-13 | 1993-07-22 | Michael D. Been | Molecules possedant une activite enzymatique de clivage de l'arn |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| ATE180101T1 (de) | 1992-08-04 | 1999-05-15 | Thomson Brandt Gmbh | Hochspannungs-zeilentransformator für einen fernsehempfänger |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5721099A (en) | 1992-10-01 | 1998-02-24 | Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
| US5440016A (en) | 1993-06-18 | 1995-08-08 | Torrey Pines Institute For Molecular Studies | Peptides of the formula (KFmoc) ZZZ and their uses |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5688997A (en) | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| US5688696A (en) | 1994-12-12 | 1997-11-18 | Selectide Corporation | Combinatorial libraries having a predetermined frequency of each species of test compound |
| DE69619825T2 (de) | 1995-06-21 | 2002-10-10 | Martek Biosciences Corp., Columbia | Kombinatorische bibliotheken aus markierten biochemischen verbindungen und verfahren zu ihrer herstellung |
| US5766903A (en) * | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
| CA2158237A1 (fr) | 1995-09-13 | 1997-03-14 | Paolo Favaretto | Siege avec dossier pivotant |
| US5731423A (en) | 1996-03-21 | 1998-03-24 | Transcell Technologies, Inc. | Process for preparing sulfoxides |
| US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| US6210931B1 (en) | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
| AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
| DE10132780A1 (de) * | 2001-07-06 | 2003-01-16 | Icon Genetics Ag | Plastidäre Genexpression über autonom replizierende Vektoren |
| EP2428568B1 (fr) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Molécules de micro arn |
| EP2530157B1 (fr) | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Composés oligomères et compositions à utiliser dans la modulation de miARNs |
| WO2005030983A2 (fr) | 2003-09-26 | 2005-04-07 | Circleamp, Inc. | Amplification de polynucleotides par amplification par cercle roulant |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| DE102004025881A1 (de) | 2004-05-19 | 2006-01-05 | Beiersdorf Ag | Oligoribonukleotide zur Beeinflussung des Haarwachstums |
| DE102005001784A1 (de) | 2005-01-13 | 2006-10-05 | Beiersdorf Ag | Oligoribonukleotide zur Reduktion der Schweißbildung durch RNA-Interferenz |
| FR2885808B1 (fr) | 2005-05-19 | 2007-07-06 | Oreal | Vectorisation de dsrna par des particules cationiques et utilisation topique. |
| CA2615323A1 (fr) * | 2005-06-06 | 2007-12-21 | 454 Life Sciences Corporation | Sequencage d'extremites appariees |
| CN101292033B (zh) | 2005-08-01 | 2013-04-03 | 普渡研究基金会 | 用于活性试剂向细胞的递送的多价rna纳粒 |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | １本鎖環状ｒｎａおよびその製造方法 |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010084371A1 (fr) | 2009-01-26 | 2010-07-29 | Mitoprod | Nouvelles molécules d'arn interférent circulaire |
| WO2010093788A2 (fr) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction |
| KR101938548B1 (ko) | 2011-06-23 | 2019-01-15 | (주)아모레퍼시픽 | 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물 |
| EP2765982A1 (fr) | 2011-10-11 | 2014-08-20 | Hans Kosak | Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques |
| WO2013113326A1 (fr) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
| US9353153B2 (en) | 2012-02-09 | 2016-05-31 | Riken | Cyclic RNA and protein production method |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| RS59199B1 (sr) | 2012-05-25 | 2019-10-31 | Univ California | Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta |
| RU2663725C2 (ru) | 2012-09-04 | 2018-08-08 | Селлектис | Многоцепочечный химерный антигенный рецептор и его применения |
| WO2014082644A1 (fr) | 2012-11-30 | 2014-06-05 | WULFF, Peter, Samuel | Arn circulaire destiné à l'inhibition de micro-arn |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| DE102013005361A1 (de) | 2013-03-28 | 2014-10-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Polyribonucleotid |
| JP6625521B2 (ja) | 2013-05-15 | 2020-01-08 | リボカイン，エルエルシー | 環状ｒｎａの細胞内翻訳 |
| MX2016002044A (es) | 2013-08-16 | 2016-08-17 | Rana Therapeutics Inc | Composiciones y metodos para modular el acido ribonucleico. |
| WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
| WO2015058069A1 (fr) * | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions et procédés pour tolériser des systèmes cellulaires |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| EP3169335B8 (fr) * | 2014-07-16 | 2019-10-09 | ModernaTX, Inc. | Polynucléotides circulaires |
| EP3054017A1 (fr) | 2015-02-03 | 2016-08-10 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | ARN circulaire pour le diagnostic et traitement de maladies cardiovasculaires |
| US10227594B2 (en) | 2015-03-20 | 2019-03-12 | Conopco, Inc. | Antiperspirant composition |
| US11000547B2 (en) | 2015-06-05 | 2021-05-11 | Dana-Farber Cancer Institute, Inc. | Compositions related to rna in circularized form |
| ES2861001T3 (es) * | 2015-06-30 | 2021-10-05 | Ethris Gmbh | Polirribonucleótidos que codifican la familia del casete de unión a ATP y formulaciones de los mismos |
| EA201890640A1 (ru) | 2015-09-04 | 2018-09-28 | Токаджен Инк. | Рекомбинантные векторы, содержащие пептид 2а |
| CN105664239B (zh) | 2016-03-23 | 2018-08-07 | 成都交大麦迪克科技有限公司 | 一种自粘附皮肤修复水凝胶的制备方法 |
| NZ749593A (en) | 2016-06-20 | 2025-10-31 | Univ Leland Stanford Junior | Circular rnas and their use in immunomodulation |
| CN106222174B (zh) * | 2016-08-12 | 2020-08-04 | 青岛大学 | circRNA CHIF核苷酸在治疗心脏疾病中的用途 |
| CA3057394A1 (fr) | 2017-04-14 | 2018-10-18 | Dana-Farber Cancer Institute, Inc. | Compositions et methodes de therapie genique transitoire a stabilite amelioree |
| WO2018231990A2 (fr) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucléotides codant pour la méthylmalonyl-coa mutase |
| EP3642342A4 (fr) | 2017-06-23 | 2021-03-17 | Cornell University | Molécules d'arn, procédés de production d'arn circulaire, et procédés de traitement |
| MX2020006150A (es) | 2017-12-15 | 2020-11-11 | Flagship Pioneering Innovations Vi Llc | Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. |
| KR20210018323A (ko) | 2018-06-06 | 2021-02-17 | 매사추세츠 인스티튜트 오브 테크놀로지 | 진핵 세포에서의 번역을 위한 원형 rna |
| BR112021001343A2 (pt) | 2018-07-24 | 2021-05-04 | Flagship Pioneering Innovations Vi, Llc | composições compreendendo poliribonucleotídeos circulares e seus usos |
| CN111603477B (zh) | 2019-02-25 | 2023-06-02 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
| CA3128644A1 (fr) | 2019-03-01 | 2020-09-10 | Avak Kahvejian | Polyribonucleotides et leurs utilisations cosmetiques |
| MA55082A (fr) | 2019-03-01 | 2022-01-05 | Flagship Pioneering Innovations Vi Llc | Compositions, procédés, et kits pour l'administration de polyribonucléotides |
| KR20210135265A (ko) | 2019-03-04 | 2021-11-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드 및 그의 약제학적 조성물 |
| EP3946466A2 (fr) | 2019-03-25 | 2022-02-09 | Flagship Pioneering Innovations VI, LLC | Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées |
| WO2020237227A1 (fr) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Compositions et procédés d'arn circulaire |
| US20220257794A1 (en) | 2019-06-14 | 2022-08-18 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
| US20220296729A1 (en) | 2019-06-19 | 2022-09-22 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
| US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| EP4096682A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions de translation et procédés d'utilisation associés |
| CN115279415A (zh) | 2020-01-29 | 2022-11-01 | 旗舰创业创新第六有限责任公司 | 用于蛋白调节的包含线性多核糖核苷酸的组合物及其用途 |
| TW202142239A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 包含環狀多核糖核苷酸之組合物之遞送 |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| CA3179444A1 (fr) | 2020-05-20 | 2021-11-25 | Avak Kahvejian | Compositions immunogenes et leurs utilisations |
| EP4153152A1 (fr) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de production d'anticorps polyclonaux humains |
-
2018
- 2018-12-14 MX MX2020006150A patent/MX2020006150A/es unknown
- 2018-12-14 SG SG11202005060YA patent/SG11202005060YA/en unknown
- 2018-12-14 US US16/772,678 patent/US12357653B2/en active Active
- 2018-12-14 BR BR112020011670-0A patent/BR112020011670A2/pt unknown
- 2018-12-14 AU AU2018385757A patent/AU2018385757B2/en active Active
- 2018-12-14 EP EP18887999.3A patent/EP3724208A4/fr active Pending
- 2018-12-14 MA MA051155A patent/MA51155A/fr unknown
- 2018-12-14 CN CN202510933666.0A patent/CN120774994A/zh active Pending
- 2018-12-14 CA CA3084824A patent/CA3084824A1/fr active Pending
- 2018-12-14 JP JP2020552672A patent/JP2021508490A/ja active Pending
- 2018-12-14 CN CN201880081133.2A patent/CN111819185A/zh active Pending
- 2018-12-14 KR KR1020207019809A patent/KR20200127152A/ko not_active Ceased
- 2018-12-14 WO PCT/US2018/065836 patent/WO2019118919A1/fr not_active Ceased
- 2018-12-14 IL IL316195A patent/IL316195A/en unknown
- 2018-12-14 CN CN202510933687.2A patent/CN120737150A/zh active Pending
- 2018-12-14 IL IL275205A patent/IL275205B2/en unknown
-
2019
- 2019-06-11 US US16/438,073 patent/US10953033B2/en active Active
-
2021
- 2021-02-11 US US17/173,991 patent/US11058706B2/en active Active
- 2021-05-06 US US17/313,963 patent/US11160822B2/en active Active
- 2021-09-22 US US17/482,346 patent/US11458156B2/en active Active
-
2022
- 2022-08-30 US US17/898,947 patent/US20230070937A1/en active Pending
- 2022-11-16 US US17/988,007 patent/US11844759B2/en active Active
-
2023
- 2023-07-04 JP JP2023109861A patent/JP2023126888A/ja active Pending
- 2023-12-18 US US18/543,966 patent/US20240122959A1/en not_active Abandoned
-
2024
- 2024-01-17 AU AU2024200298A patent/AU2024200298A1/en active Pending
-
2025
- 2025-06-16 US US19/239,068 patent/US20250381211A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51155A (fr) | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations | |
| EP3419676A4 (fr) | Compositions antimicrobiennes et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3328199A4 (fr) | Compositions antimicrobiennes et leurs utilisations | |
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
| EP3370528A4 (fr) | Compositions probiotiques et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3179870C0 (fr) | Composés et compositions antimicrobiens ainsi que leurs utilisations | |
| EP3344624A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations |